At present, Non-Communicable diseases (NCDs) have become important issues of public health in Thailand, according to the WHO found that the NCDs have become a major cause of death over 60 percent of all causes. They compose of death from heart disease, Stroke, diabetes, cancers and chronic respiratory diseases. The data showed that the incidences of this disease in Thailand are increasing exponentially every year. If no control measures to reduce the risk of diseases, this problem is becoming increasingly severe. This will affect the quality of life of the population and the economy of the country.
In order to reduce the incidence of NCDs in general, it there is a great need to start on a personal level. Therefore, it is important to understand Thais’ perception in personal health care and risk factors that could affect spur these diseases. After we understand people’s behaviors, it could be used to develop effective measures to prevent NCDs them. It is estimated that more than 50 percent of the rate of death and disability due to NCDs are preventable. Such numbers call for a broad collaboration between Therefore considered a common good that the pharmaceutical industry, civil society and government agencies to participate in the on activity for the disease prevention programs to help eliminate and address the risk factors that lead to the diseases. The end result will not only be limited to the better health of Thai people but it will also lead to a reduction in the budget for the treatment of NCDs care in the future.
Health is wealth. Nowhere is this more poignantly evident than in areas where NTDs are present and impede economic development. Taking steps to reduce the toll of NTDs takes long-term and wide-ranging commitment from governments, civil society and business. The research-based biopharmaceutical industry has stepped up to the plate, not only with historic levels of drug donations, but also with long-term commitment to R&D. The 100-plus active research projects for NTDs, and growing year-on-year research funding in this area, are boosting innovation to combat NTDs.How is pharma contributing to the global fight against NTDs?